 |
 |

Livedoid Vasculopathy
What It Is and How the Patient Should Be Evaluated and Treated
Arch Dermatol. 2006;142:1481-1482.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In this issue of the ARCHIVES are 2 articles that aid us in defining associated conditions in patients with livedoid vasculopathy (LV). Hairston et al1 demonstrate that thrombophilic conditions occur frequently in patients with LV, including inherited abnormalities and acquired disease. In addition, they note a wide variety of associated conditions, including connective tissue diseases and neoplasia. Deng et al2 used tissue plasminogen activator (tPA) to successfully manage LV in a patient who was found to have elevated levels of plasminogen activator inhibitor-1 owing to a homozygous mutation of the plasminogen activator inhibitor-1 promoter. They note that patients with elevated levels of plasminogen activator inhibitor-1 have a propensity for thrombotic disorders. Their patient experienced 4 relapses of LV generally associated with discontinuation of antithrombotic therapy. In each instance, the lesions responded to reinstitution of tPA infusions.
In 1998, Jorizzo,3 in an editorial about an article by Papi et al,4 . . . [Full Text of this Article] AUTHOR INFORMATION
Jeffrey P. Callen, MD
RELATED ARTICLES
Livedoid Vasculopathy: Further Evidence for Procoagulant Pathogenesis
Bethany R. Hairston, Mark D. P. Davis, Mark R. Pittelkow, and Iftikhar Ahmed
Arch Dermatol. 2006;142(11):1413-1418.
ABSTRACT
| FULL TEXT
Livedoid Vasculopathy Associated With Plasminogen Activator Inhibitor-1 Promoter Homozygosity (4G/4G) Treated Successfully With Tissue Plasminogen Activator
April Deng, Christopher D. Gocke, John Hess, Meyer Heyman, Michael Paltiel, and Anthony Gaspari
Arch Dermatol. 2006;142(11):1466-1469.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hyperhomocysteinemia and Lower Extremity Wounds
Schwartzfarb and Romanelli
INT J LOW EXTREM WOUNDS 2008;7:126-136.
ABSTRACT
Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy
Zeni et al.
Ann Rheum Dis 2008;67:1055-1056.
FULL TEXT
|